87 related articles for article (PubMed ID: 15345665)
1. Beating ischemia: a new feat of EETs?
Bhatnagar A
Circ Res; 2004 Sep; 95(5):443-5. PubMed ID: 15345665
[No Abstract] [Full Text] [Related]
2. Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway.
Seubert J; Yang B; Bradbury JA; Graves J; Degraff LM; Gabel S; Gooch R; Foley J; Newman J; Mao L; Rockman HA; Hammock BD; Murphy E; Zeldin DC
Circ Res; 2004 Sep; 95(5):506-14. PubMed ID: 15256482
[TBL] [Abstract][Full Text] [Related]
3. Cytochrome P450 and arachidonic acid metabolites: role in myocardial ischemia/reperfusion injury revisited.
Gross GJ; Falck JR; Gross ER; Isbell M; Moore J; Nithipatikom K
Cardiovasc Res; 2005 Oct; 68(1):18-25. PubMed ID: 15993870
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of cytochrome P450omega-hydroxylase: a novel endogenous cardioprotective pathway.
Nithipatikom K; Gross ER; Endsley MP; Moore JM; Isbell MA; Falck JR; Campbell WB; Gross GJ
Circ Res; 2004 Oct; 95(8):e65-71. PubMed ID: 15388642
[TBL] [Abstract][Full Text] [Related]
5. Roles of epoxyeicosatrienoic acids in vascular regulation and cardiac preconditioning.
Gauthier KM; Yang W; Gross GJ; Campbell WB
J Cardiovasc Pharmacol; 2007 Dec; 50(6):601-8. PubMed ID: 18091575
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450 2J3/epoxyeicosatrienoic acids mediate the cardioprotection induced by ischaemic post-conditioning, but not preconditioning, in the rat.
Yu GG; Zeng XJ; Wang HX; Lu LQ; Zheng SP; Ma LQ; Chang J; Wang J; Zhang DM; Du FH; Zhang LK
Clin Exp Pharmacol Physiol; 2011 Jan; 38(1):63-70. PubMed ID: 21105892
[TBL] [Abstract][Full Text] [Related]
7. Cytochrome P450: major player in reperfusion injury.
Gottlieb RA
Arch Biochem Biophys; 2003 Dec; 420(2):262-7. PubMed ID: 14654065
[TBL] [Abstract][Full Text] [Related]
8. Cardiac and vascular KATP channels in rats are activated by endogenous epoxyeicosatrienoic acids through different mechanisms.
Lu T; Ye D; Wang X; Seubert JM; Graves JP; Bradbury JA; Zeldin DC; Lee HC
J Physiol; 2006 Sep; 575(Pt 2):627-44. PubMed ID: 16793897
[TBL] [Abstract][Full Text] [Related]
9. Cytochrome P450 2J2 promotes the neoplastic phenotype of carcinoma cells and is up-regulated in human tumors.
Jiang JG; Chen CL; Card JW; Yang S; Chen JX; Fu XN; Ning YG; Xiao X; Zeldin DC; Wang DW
Cancer Res; 2005 Jun; 65(11):4707-15. PubMed ID: 15930289
[TBL] [Abstract][Full Text] [Related]
10. Determination of cytochrome P450 metabolites of arachidonic acid in coronary venous plasma during ischemia and reperfusion in dogs.
Nithipatikom K; DiCamelli RF; Kohler S; Gumina RJ; Falck JR; Campbell WB; Gross GJ
Anal Biochem; 2001 May; 292(1):115-24. PubMed ID: 11319825
[TBL] [Abstract][Full Text] [Related]
11. Regio- and stereoselective epoxidation of arachidonic acid by human cytochromes P450 2C8 and 2C9.
Daikh BE; Lasker JM; Raucy JL; Koop DR
J Pharmacol Exp Ther; 1994 Dec; 271(3):1427-33. PubMed ID: 7996455
[TBL] [Abstract][Full Text] [Related]
12. Brain synthesis and cerebrovascular action of cytochrome P-450/monooxygenase metabolites of arachidonic acid.
Ellis EF; Amruthesh SC; Police RJ; Yancey LM
Adv Prostaglandin Thromboxane Leukot Res; 1991; 21A():201-4. PubMed ID: 1825540
[No Abstract] [Full Text] [Related]
13. Activation of RISK and SAFE pathways is not involved in the effects of Cx43 deficiency on tolerance to ischemia-reperfusion injury and preconditioning protection.
Sánchez JA; Rodríguez-Sinovas A; Barba I; Miró-Casas E; Fernández-Sanz C; Ruiz-Meana M; Alburquerque-Béjar JJ; García-Dorado D
Basic Res Cardiol; 2013 May; 108(3):351. PubMed ID: 23595215
[TBL] [Abstract][Full Text] [Related]
14. The cytochrome P450 metabolic pathway of arachidonic acid in the cornea.
Schwartzman ML; Davis KL; Nishimura M; Abraham NG; Murphy RC
Adv Prostaglandin Thromboxane Leukot Res; 1991; 21A():185-92. PubMed ID: 1847765
[No Abstract] [Full Text] [Related]
15. Participation of epoxygenase activation in saikogenin D-induced inhibition of prostaglandin E(2) synthesis.
Toriniwa Y; Lv X; Kodama Y; Ohizumi Y; Yoshida M; Nakahata N
J Pharm Pharmacol; 2006 Jun; 58(6):859-66. PubMed ID: 16734988
[TBL] [Abstract][Full Text] [Related]
16. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2.
Spiecker M; Darius H; Hankeln T; Soufi M; Sattler AM; Schaefer JR; Node K; Börgel J; Mügge A; Lindpaintner K; Huesing A; Maisch B; Zeldin DC; Liao JK
Circulation; 2004 Oct; 110(15):2132-6. PubMed ID: 15466638
[TBL] [Abstract][Full Text] [Related]
17. Chiral resolution of the epoxyeicosatrienoic acids, arachidonic acid epoxygenase metabolites.
Wei S; Brittin JJ; Falck JR; Anjaiah S; Nithipatikom K; Cui L; Campbell WB; Capdevila JH
Anal Biochem; 2006 May; 352(1):129-34. PubMed ID: 16480681
[TBL] [Abstract][Full Text] [Related]
18. Role of Ca2+-independent phospholipase A2 and cytochrome P-450 in store-operated calcium entry in 3T6 fibroblasts.
Martínez J; Moreno JJ
Biochem Pharmacol; 2005 Sep; 70(5):733-9. PubMed ID: 15993852
[TBL] [Abstract][Full Text] [Related]
19. Review article: epoxyeicosatrienoic acids: novel mediators of cardioprotection.
Nithipatikom K; Gross GJ
J Cardiovasc Pharmacol Ther; 2010 Jun; 15(2):112-9. PubMed ID: 20200327
[TBL] [Abstract][Full Text] [Related]
20. Epoxyeicosatrienoic acids limit damage to mitochondrial function following stress in cardiac cells.
Katragadda D; Batchu SN; Cho WJ; Chaudhary KR; Falck JR; Seubert JM
J Mol Cell Cardiol; 2009 Jun; 46(6):867-75. PubMed ID: 19285984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
